Evidation Health, a San Mateo, CA-based provider of a privacy-first, direct-to-person research platform, closed a $45m Series D funding.
The round was led by B Capital with participation from new investors McKesson Ventures and Section 32 as well as existing investors Revelation Partners, Rethink Impact, and SV Health Investors. In conjunction with the funding, B Capital’s Adam Seabrook has joined Evidation’s Board of Directors.
Founded in 2012 and led by CEO Deborah Kilpatrick, Ph.D., Evidation measures health in everyday life and enables anyone to participate in research and health programs via its Achievement platform, which is used by millions of individuals. The company partners with healthcare companies to understand health and disease outside the clinic.
The company will use this new capital to build upon its existing evidence generation capabilities to offer real-time insights and digital tools to its network of nearly 4 million individuals. Evidation will leverage this investment to continue to grow its study solutions business and offer programs that enable Achievement members to gain clinically actionable insights into their health. These include relevant digital interventions, treatments, and tools to help individuals understand and take advantage of the latest evidence, in partnership with their care teams. The company will continue to expand and diversify the Achievement population to serve additional at-risk and disease-specific cohorts.